None listed
Conditions
Interventions
- Chemo with CHOP scheme (6 -8 cycles) to be repeated every 21 days.
- Rituximab on day 1 of each of the 6 to 8 programmed cycles.
- IT Chemotherapy: MTX weekly, in weeks 1,2,3,4
- Prophylactic scrotal radiotherapy.
- Radiotherapy in the field involved (diseases with stage II).
Sponsors
INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,
Eligibility
Inclusion criteria
Inclusion criteria: NLC Testicular Primary Stage 1 to II Ann Arbor Untreated disease Evaluable, measurable two-dimensionally or without evidence of diseases Age = 18 years ECOG performance status 0-2.
Exclusion criteria
Exclusion criteria: - Impaired renal function (creatinine> 2 mg / day) or liver function (bilimibin> 2mg / di) except due to lymphoma. - Patients with HIV positive - Evolutionary malignancy within 5 years with the exception of cancer Localized skin does not melamomic.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Adverse Events Serious. Unacceptable toxicity, defined as unpredictable, irreversible or grade 4. The refusal of the patient to continue therapy. Measure:Therapeutic activity of systematic chemotherapy combined with the addition of Rituximab + Qt. intrathecal + loco-regional radiotherapy in primary testicular DLCL. Timepoints:at month | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Countries
Peru
Outcome results
None listed